Comparing the Prognostic Value of PTEN and Akt Expression with the Mitotic Activity Index in Adjuvant Chemotherapy-Treated Node-Negative Breast Cancer patients aged <55 years
| Autor: | Arne Nysted, Ivar Skaland, Kjell H. Kjellevold, Emiel A. M. Janssen, Jon Arne Søreide, Håvard Søiland, Jan P. A. Baak, Einar Gudlaugson |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male Oncology PTEN Cancer Research medicine.medical_specialty Cyclophosphamide medicine.medical_treatment Breast Neoplasms lcsh:RC254-282 Disease-Free Survival Pathology and Forensic Medicine Breast cancer Internal medicine Mitotic Index medicine Humans lcsh:QH573-671 Protein kinase B PI3K/AKT/mTOR pathway biology lcsh:Cytology business.industry Hazard ratio PTEN Phosphohydrolase Cell Biology General Medicine Middle Aged Prognosis Mitotic Activity Index lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Immunohistochemistry cell proliferation Chemotherapy Adjuvant Lymphatic Metastasis biology.protein Molecular Medicine Female Methotrexate Other business Proto-Oncogene Proteins c-akt Adjuvant Akt pathway medicine.drug |
| Zdroj: | Cellular Oncology, Vol 29, Iss 1, Pp 25-35 (2007) Cellular Oncology : the Official Journal of the International Society for Cellular Oncology |
| ISSN: | 2210-7185 2210-7177 |
| DOI: | 10.1155/2007/569246 |
| Popis: | Background: The prognostic value of the PI3K/Akt/mTOR pathway and PTEN in invasive breast cancer (IBC) is controversial. Cell proliferation, especially the Mitotic Activity Index (MAI), is strongly prognostic in lymph node-negative (LNneg) invasive breast cancer. However, its prognostic value has not been compared with the value of Akt and PTEN expression. Material and Methods: Prognostic comparison of Her2Neu, p110alpha (PIK3CA), Akt, mTOR, PTEN, MAI and cell-cycle regulators in 125 LNneg patients aged Results: Twenty-one (17%) patients developed distant metastases = DMs (median follow-up: 134 months). p110alpha correlated (p = 0.01) with pAkt but only in PTEN-negatives; pAkt correlated (p = 0.02) with mTOR. PTEN-negativity correlated with high MAI, high grade and ER-negativity (p = 0.009). The MAI was the strongest prognosticator (Hazard Ratio = HR = 2.9, p = 0.01). Her2Neu/p110α/Akt/mTOR features have no additional prognostic value to the MAI. PTEN had additional value but only in MAI < 3 (39/125 = 31%; 8% DMs). 19/39 = 49% of the MAI < 3 patients have combined MAI < 3 / PTEN+ with 0% DMs, contrasting 15% DMs in MAI < 3 / PTEN− (p = 0.03). Conclusions: In T1−3N0M0 adjuvant CMF-treated breast cancer patients aged |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|